New Hepatitis B Virus Study Results Reported from Peking Union Medical College Hospital (Genetically-modified, redirected T cells target hepatitis B surface antigen-positive hepatocytes and hepatocellular carcinoma lesions in a clinical setting).

A recent study conducted at Peking Union Medical College Hospital in Beijing, China, focused on genetically-modified T cells targeting hepatitis B surface antigen-positive hepatocytes and hepatocellular carcinoma lesions. The study involved the use of SCG101, an autologous, HBV-specific T-cell product, which showed promising efficacy and safety in preclinical models and in a patient with primary HBV-HCC. The treatment resulted in the elimination of HBsAg+ cells and sustained tumor control after a single dosing, indicating potential for future therapeutic applications in hepatitis B-related liver cancer. [Extracted from the article]